PVCT - Provectus concludes patient enrollment in early-stage neuroendocrine tumors study

Provectus ([[PVCT]] -2.9%) has completed enrollment of 12 patients for its Phase 1 of cancer immunotherapy PV-10, an injectable formulation of its proprietary rose bengal disodium, for the treatment of symptomatic neuroendocrine tumors metastatic to the liver, refractory to somatostatin analogs and peptide receptor radionuclide therapy.Recently, the company announced positive preliminary data from its Phase 1b/2 study of PV-10 in combination with Merck's KEYTRUDA for cutaneous melanoma in patients.The company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods administration in Q1 2021.

For further details see:

Provectus concludes patient enrollment in early-stage neuroendocrine tumors study